MEDIFAST INC (MED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MEDIFAST INC (MED) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($12.11 Million) by net assets ($214.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MEDIFAST INC - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how MEDIFAST INC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MEDIFAST INC debt and liabilities for a breakdown of total debt and financial obligations.
MEDIFAST INC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MEDIFAST INC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Roto Pumps Limited
NSE:ROTO
|
0.029x |
|
Treace Medical Concepts Inc
NASDAQ:TMCI
|
-0.102x |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
0.079x |
|
Sagittarius Life Science
TWO:3205
|
0.000x |
|
We&Win Diversification Co Ltd
TWO:4113
|
-0.061x |
|
Noroo Paint
KO:090350
|
-0.006x |
|
Thai Steel Cable Public Company Limited
BK:TSC
|
0.023x |
|
Paragon Technologies Co Ltd
TW:3518
|
0.087x |
Annual Cash Flow Conversion Efficiency for MEDIFAST INC (1996–2024)
The table below shows the annual cash flow conversion efficiency of MEDIFAST INC from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see market value of MEDIFAST INC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $210.11 Million | $24.48 Million | 0.116x | -84.10% |
| 2023-12-31 | $201.48 Million | $147.66 Million | 0.733x | -41.60% |
| 2022-12-31 | $155.04 Million | $194.57 Million | 1.255x | +168.75% |
| 2021-12-31 | $202.47 Million | $94.55 Million | 0.467x | -49.43% |
| 2020-12-31 | $157.25 Million | $145.20 Million | 0.923x | +14.88% |
| 2019-12-31 | $104.83 Million | $84.26 Million | 0.804x | +44.20% |
| 2018-12-31 | $109.11 Million | $60.82 Million | 0.557x | +39.98% |
| 2017-12-31 | $108.58 Million | $43.24 Million | 0.398x | +50.82% |
| 2016-12-31 | $96.02 Million | $25.35 Million | 0.264x | -20.48% |
| 2015-12-31 | $88.58 Million | $29.41 Million | 0.332x | +4.63% |
| 2014-12-31 | $80.48 Million | $25.54 Million | 0.317x | -26.28% |
| 2013-12-31 | $98.42 Million | $42.36 Million | 0.430x | -2.95% |
| 2012-12-31 | $90.79 Million | $40.26 Million | 0.444x | -6.64% |
| 2011-12-31 | $73.40 Million | $34.87 Million | 0.475x | +18.82% |
| 2010-12-31 | $71.96 Million | $28.77 Million | 0.400x | +4.18% |
| 2009-12-31 | $52.93 Million | $20.31 Million | 0.384x | +166.54% |
| 2008-12-31 | $38.17 Million | $5.50 Million | 0.144x | -41.32% |
| 2007-12-31 | $32.42 Million | $7.95 Million | 0.245x | +18.23% |
| 2006-12-31 | $28.17 Million | $5.84 Million | 0.208x | +42.23% |
| 2005-12-31 | $22.02 Million | $3.21 Million | 0.146x | +20.17% |
| 2004-12-31 | $19.21 Million | $2.33 Million | 0.121x | +18.62% |
| 2003-12-31 | $17.08 Million | $1.75 Million | 0.102x | -76.75% |
| 2002-12-31 | $5.58 Million | $2.46 Million | 0.440x | +71.66% |
| 2001-12-31 | $2.54 Million | $651.00K | 0.257x | +1510.76% |
| 2000-12-31 | $1.21 Million | $-22.00K | -0.018x | -102.62% |
| 1999-12-31 | $-213.00K | $-148.00K | 0.695x | +173.63% |
| 1998-12-31 | $2.15 Million | $-2.03 Million | -0.944x | +0.03% |
| 1997-12-31 | $2.02 Million | $-1.90 Million | -0.944x | -2291.62% |
| 1996-12-31 | $5.57 Million | $-220.00K | -0.039x | -- |
About MEDIFAST INC
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. … Read more